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Background: As the health services in Ireland have become more resource-constrained, pressure has increased to
reduce public spending on community drug schemes such as General Medical Services (GMS) drug prescribing and
to understand current and future trends in prescribing. The GMS scheme covers approximately 37% of the Irish
population in 2011 and entitles them, inter alia, to free prescription drugs and appliances. This paper projects the effects
of future changes in population, coverage, claims rates and average claims cost on GMS costs in Ireland.
Methods: Data on GMS coverage, claims rates and average cost per claim are drawn from the Primary Care
Reimbursement Service (PCRS) and combined with Central Statistics Office (CSO) (Regional and National Population
Projections through to 2026). A Monte Carlo Model is used to simulate the effects of demographic change (by region,
age, gender, coverage, claims rates and average claims cost) will have on GMS prescribing costs in 2016, 2021 and 2026
under different scenarios.
Results: The Population of Ireland is projected to grow by 32% between 2007 and 2026 and by 96% for the over 70s.
The Eastern region is estimated to grow by 3% over the lifetime of the projections at the expense of most other regions.
The Monte Carlo simulations project that females will be a bigger driver of GMS costs than males. Midlands region will
be the most expensive of the eight old health board regions. Those aged 70 and over and children under 11 will be
significant drivers of GMS costs with the impending demographic changes. Overall GMS medicines costs are projected
to rise to €1.9bn by 2026.
Conclusions: Ireland’s population will experience rapid growth over the next decade. Population growth coupled with
an aging population will result in an increase in coverage rates, thus the projected increase in overall prescribing costs.
Our projections and simulations map the likely evolution of GMS cost, given existing policies and demographic trends.
These costs can be contained by government policy initiatives.
Keywords: GMS prescribing, Monte carlo simulation model, Regional variation, Scenario analysisBackground
Many of the developed economies, including Ireland,
are struggling to contain expenditure on health follow-
ing the fiscal crisis in the aftermath of the 2008 global
economic recession. Expenditure on pharmaceuticals
is one of the fastest growing elements of total health
spending within the European Union (EU). Pharma-
ceutical expenditure exceeded €180 billion in 2008* Correspondence: aisling.conway@cit.ie
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unless otherwise stated.within the EU and accounted, on average, for approxi-
mately 17 per cent of EU countries’ total expenditure
on health [1]. In 2009, Ireland had one of the highest
pharmaceutical spends per capita of the Organisation
for Economic Co-operation and Development (OECD)
countries after the US, Canada and Greece [2]. In Ireland,
pharmaceutical expenditure accounted for 16.9 per cent
of total health expenditure in 2007 and pharmaceutical
spend per capita was €446.37, peaking at 17.9 per cent
and €501.48 in 2010 [3]. Community Drugs Schemes
(CDS) in Ireland consist of the General Medical Services
(GMS), the Long Term Illness (LTI) Scheme, Drugl Ltd. This is an Open Access article distributed under the terms of the Creative
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Scheme (HTDS). CDS expenditure on medicines accounted
for approximately 85 per cent of total drug expenditure in
Ireland in 2007 [4]. The annual cost of medicines under
community drug schemes in Ireland increased from €564 m
in 2000 to €1,961 m in 2009 before falling by an esti-
mated 8 per cent by 2011 following a series of cost
containment measures [1].
The focus of this paper is the GMS scheme which is
the largest of the schemes with 36.9 per cent of the
population eligible in 2011 [5]. Those who are eligible
for the GMS scheme (medical card holders) are entitled
to free prescription drugs and appliances with a nominal
charge per item (€0.50) introduced in budget 2011 . Cost
of Medicines on the GMS scheme more than trebled be-
tween 2000 and 2009 from approximately €338 million
to €1,260 million. Overall, costs of medicines were ap-
proximately €1,048 million in 2007 and increased by
15.2 per cent to approximately €1,207 million in 2011.
Following a sharp contraction in the Irish economy in
2008, resulting in mounting fiscal deficits, the sustain-
ability of funding these community drug schemes have
come under the spotlight of the EU, International Mon-
etary Fund (IMF) and European Central Bank (ECB)
(Troika) who have set stringent targets for reducing drug
costs as conditions of the bailout programme. Whilst
the troika’s main cost containment measure is on the
substitution from proprietary to generic prescribing, the
challenge for Ireland and many of our EU counterparts
in containing expenditure on pharmaceuticals is severely
restricted by the growth in the elderly component of our
populations, the sub-group with the greatest consumption
of prescribed drugs. Projections by the Central Statistics
Office (CSO) show the number of elderly people in
Ireland will have grown by 200,000 by 2021 [6].
The literature highlights six cost drivers of drug ex-
penditure; population growth, population aging, general
inflation, price effects, volume effects and mix of drugs
[7]. Whilst Irish drug pricing is substantially higher than
our UK counterparts [8], the ESRI identifies population
growth and population aging as the key drivers of future
drug costs [2]. People in developed economies are living
longer, with life expectancy at their highest level and
population projections predicting significant increases in
the total number of older people. The proportion of
people who are very old is growing fastest and this num-
ber is expected to almost double by 2030. According to
the World Health Organisation, the present and future
generations of older people can also expect to live for
considerably longer than their predecessors.
This paper assesses the implications of demographic
change and policy scenarios on future GMS costs in
Ireland from 2007 through to 2026. GMS costs are de-
termined by population, GMS coverage, claims rate andthe average cost per claim and assumptions were made
around these four variables For this analysis, the cover-
age rate is defined as the proportion of the population
eligible for the GMS scheme and the claims rate is the
percentage of those covered who make a claim. The
average cost per claim is the total cost of claimants di-
vided by the number of claimants.
Predictions of drug utilisation and costs have been
undertaken in several international studies [9,10]. A
fixed effects model was used to predict the impact of
regulation on pharmaceutical cost in 19 countries from
1992 to 2004, finding that regulations reduce pharmaceut-
ical revenues significantly [9]. A Spanish study investi-
gated the capacity to predict future high-cost patients in
Spain through c-statistic, sensitivity and specificity param-
eters finding that pharmacy-based predictive models can
assist administrators and medical directors in planning
the health budget and identifying high-cost-risk patients
amenable to care management programs [10]. A number
of predictive studies have been undertaken in the United
States on future health care costs, which also inform fu-
ture prescribing costs [11-13]. These studies predicted
drug expenditures for the Medicare scheme [11] and a
veteran health population [12], respectively, and their
models included demographic and health status variables.
Both [11,12] found combined drug and diagnostic data are
superior in predicting total health care costs. A compari-
son of the predictive performance of diagnosis and drug
based models to determine health care costs in the US
found drug based models predict future pharmacy costs
more effectively than diagnosis based models and a com-
bined drug and diagnostic model is a better predictor of
future health care costs than either model alone [13].
In terms of the most relevant studies in Ireland, a lin-
ear current use model on 2006 data, and a regression
model, was used to project future prescribing for the
three community drug schemes [14]. They predicted
that ingredient costs are likely to be between €1.5bn and
€2.3bn for the three Community drug schemes (GMS,
LTI & DPS) by 2020 with the largest increase in the
GMS scheme. The ingredient cost incorporates approxi-
mately 80 per cent of the total cost of prescriptions. The
total cost of prescriptions is comprised of the ingredient
cost, dispensing fee and VAT. This paper updates and
expands the Bennett et al. (2009) projections for the
GMS scheme only. In addition, this paper includes
demographic and regional population changes, policy
variables and provides a Monte Carlo sensitivity ana-
lysis of the results. A regional examination of chronic
conditions influencing drug prescribing found that regional
factors were highly variable in Ireland and significant [15],
whilst an investigation into the prescribing prevalence of
insulin dependent and non-insulin dependent diabetes
again found a significant variation between regions [16].
Conway et al. BMC Health Services Research 2014, 14:477 Page 3 of 10
http://www.biomedcentral.com/1472-6963/14/477Methods
The main source of data is the PCRS Statistical Analysis
of Claims and Payments, Annual Reports and a sample
2007 PCRS database. The sample database consists of
192,000 observations extracted from the GMS popula-
tion claims data. The base year used is 2007 and the
geographical area is the former Health Board, of which
there are 8. The first 100 observations by gender and
age cohort in each monthly file was used in this analysis.
For example, 0–5 Eastern male, there are 100 observa-
tions. 192,000/100 = 16,000 in each month. The variables
in the database include; ingredient cost, VAT, dispensing
fee, total cost, number of items and number of forms
and are disaggregated by month (12), age cohort (10),
gender (2) and region (8). Claims rate and average cost
per claim were estimated using the sample PCRS data-
base. For our analysis, the data is disaggregated by 10
age cohorts, 2 genders and 8 regions for each of the four
variables. The data used in this paper was granted by the
Health Service Executive (HSE) and is anoymised where
individuals are not identified, the data does not have a
unique user identifier. Therefore, it was unnecessary to
seek ethical approval.
Population data was sourced from the CSO Regional
Population Projections 2011–2026. Data was detailed by
year of age, gender, county and region, taking account of
international migration, fertility and inter-regional flows.
In order to conform to HSE age cohorts, the CSO data
were reconciled into ten age cohorts. The CSO regions
(Border, Mid-East, Dublin) were not reconcilable with
three of the old health board regions (North-West,
North-East, Eastern). An adjustment factor based on the
2006 Census was applied to form the North-West,
North-East and Eastern regions to conform to the old
health board regions.
Coverage 2007 was estimated from the PCRS annual
report and CSO population projections. Medical card
coverage was 30.1 per cent (1,276,178 persons) of the
population in 2007 [17] increasing to 36.9 per cent
(1,694,063) in 2011 [5]. The minimum, mean and max-
imum 2007 scenarios were calculated based on historical
coverage data between 1996 and 2010. Three scenarios
were estimated for 2011 based on historical coverage
data between 1996 and 2011 to form three coverage sce-
narios by region, gender and age cohort (RGA).
Coverage projections for 2016, 2021 and 2026 were es-
timated using 2011 coverage data, as this was the most
up to date data available at the time of projections. The
projected mean population was used to estimate the
coverage and the number of eligible persons for each
scenario by RGA in 2016, 2021 and 2026. If the older
age cohorts (70–74, >75) for each region and gender
exceeded 1.00, an adjustment factor was applied with
lambda taking any value between 0 and 0.99. For example,if the projected population for >75 in a given region is 100
but the number of projected GMS eligible persons is 105,
GMS coverage rate is 1.05. As this value exceeds 1.00, the
adjustment factor below was applied to scale the value
below 1.00.
Adjustment Factor ¼Min >75 – λ 1:00 – 70‐74 age cohortð Þð Þ
The claims rate was estimated using both the PCRS
2007 annual report and a sample 2007 PCRS database.
For this analysis, the claims rate is the proportion of med-
ical card holders who make a claim. Of the 1,276,178
medical card holders in 2007, 1,225,131 made a claim on
the card giving a claims rate of 96 per cent in 2007. A 95
per cent confidence interval was applied, establishing a
lower bound (minimum scenario) and upper bound (max-
imum scenario) around the mean claims rate. For this
analysis, the claims rate was assumed to remain at the
2007 level throughout the lifetime of the projections . This
is borne out by It was found that the introduction of a 50
cent co-payment charge in 2010 did not affect patient de-
mand for drugs [18]. Furthermore, the national claims rate
has not changed since the co-payment introduction. 93
per cent of eligible GMS persons availed of services in
2010 and 2011 [5,19].
The average cost (ac) per claim was determined from
the sample 2007 PCRS database which is the total cost of
claimants divided by the number of claimants. More than
96 per cent of all GMS eligible persons availed of services
in 2007 with an average pharmacy cost of €856.14 per per-
son [17]. A 95 per cent confidence interval was applied,
establishing a lower bound (minimum scenario) and upper
bound (maximum scenario) around the mean cost per
claim. Historical ac per claim growth rates were deter-
mined and we assumed the historical growth evolution
would continue in estimating the ac per claim for 2011
and projections between 2016 and 2026.
The utilisation and expenditure on drugs are difficult to
forecast due to uncertainties about the rate of adoption of
new medicines and various ongoing health care reforms
and activities to improve the quality and efficiency of
prescribing. The Monte Carlo Simulation (MCS) model
employs statistical sampling to forecast under uncertainty.
MCS generates a large number (100,000) of outcomes
which is representative of your decision and assesses
your decisions and the impact of risk, allowing for better
decision making under uncertainty. Taking a large number
of simulations as we have done, gives an excellent ap-
proximation to the true distribution of projected cost.
The equation used for simulations is;
Probable cost ¼ Expected cost þ error
where error is an ensemble for the Monte Carlo simu-
lation, having a normal distribution with zero mean and
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an MCS model avoided bias in health economic model-
ling [20]. The MCS model identifies uncertain variables
(explanatory variables) and uncertain functions (dependent
variables). The uncertain variables are population, cover-
age, claims rate and ac per claim and the uncertain func-
tion is the total costs of GMS scheme. For this analysis, the
MCS model was adopted to forecast GMS costs through
to 2026.
Empirical probability (proportion) was determined by
each RGA class. The cumulative probabilities were cal-
culated which gives a weight for the occurrence of find-
ing a person in an RGA class. A macro was written in
Visual Basic Editor in Microsoft Excel to run the simula-
tions. An MCS with 100,000 iterations was used to
propagate the uncertainty in the model. It’s important to
assign an appropriate probability distribution to uncertain
variables in developing a comprehensive MCS model [21].
A Normal distribution was applied to estimate costs to
allow for uncertainty in the model. The MCS results were
imported into Minitab 16 for statistical analysis. Descrip-
tive and statistical analysis was performed in Minitab for
each scenario and an overall analysis was carried out com-
paring all three scenarios by region, gender and age co-
hort. Statistical analysis included a histogram of cost,
main effects plot, interval plot of cost by region, gender
and age cohort.
Results
The population of Ireland is projected to grow rapidly
with a sharp increase in both the birth rate and in the
elderly population. The total population is projected to
grow by 96.3 per cent over the lifetime of the projec-
tions. The projections indicate that the population will
increase from 4.3 million in 2007 to 5.7 million in 2026
(32.6% increase). The male population is estimated to30.1
36.92
0
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40
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2007 2011 20
Figure 1 Percentage GMS coverage rate projections, Ireland 2016–20increase by 33.4 per cent increase and the female popu-
lation is estimated to increase by 30.2 per cent by 2026.
In the 70 to 74 age category, there is an estimated 85.4
per cent increase between 2007 and 2026. The over 75 s
shows the largest increase over the lifetime of the pro-
jections where the population more than doubles from
208,756 in 2007 to 422,589 in 2026 (102.4%). Over 70s
projected population will increase in the first three time
periods (2007–2011, 2011–2016 and 2016–2021) and
will grow at a slower rate of 22.6 per cent between 2021
and 2026.
In terms of regional population change, the Eastern re-
gion constituted 35.5 per cent of the overall population in
2007. That proportion is projected to increase to 38.2 per
cent by 2026 whereas the Southern region will decrease
from 14.6 per cent in 2007 to 13.6 per cent in 2026. The
remaining regions will see a decrease in population apart
from the Western region which will remain constant.
We have estimated that coverage will be approximately
34.7 per cent in 2016, 37.5 per cent in 2021 and 37.2 per
cent in 2026 (Figure 1). It is estimated that the number
of eligible GMS persons will be approximately 1.8 million
in 2016, 2 million in 2021 and 2.1 million in 2026. The es-
timates of the mean claims rate and the ac per claim for
2007 are detailed in Tables 1 and 2.
The MCS model projects total pharmacy cost will
rise to €1,317 million in 2016, €1,626 million in 2021
and €1,985 million in 2026 (Figure 2), given the as-
sumptions around the 4 variables. The descriptive ana-
lysis of 100,000 simulations for scenario 2 in 2016
projected an average cost per claimant of €272.31. This
is projected to be €312.61 in 2021 and €366.81 in 2026
(Table 3). Statistical analysis for the 3 scenarios in
2016 and the main effects plot for scenario 2, 2016 show
the effect the three categorical variables have on the aver-
age cost per claimant in 2016. The main factors driving24.49
26.85
28.76
34.70
37.49 37.23
42.28
45.64 48.22
16 2021 2026
Min
Mean
Max
26.
Table 1 Mean scenario claims rate (Claims rate = Number of claimants/GMS population) 2007
Region 0 – 11 12 – 15 16 – 24 25 – 34 35 – 44 45 – 54 55 – 64 65 – 69 70 – 74 >75 Total
Eastern
Males 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Females 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Midland
Males 1.00 0.99 0.99 0.99 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Females 1.00 0.99 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Mid-Western
Males 0.93 0.88 0.90 0.91 0.91 0.94 0.96 0.9 0.97 0.99 0.93
Females 0.93 0.88 0.93 0.93 0.93 0.95 0.96 0.98 0.98 0.98 0.95
North-Eastern
Males 0.88 0.82 0.85 0.86 0.87 0.91 0.93 0.95 0.94 0.95 0.90
Females 0.88 0.82 0.91 0.90 0.90 0.92 0.95 0.94 0.96 0.95 0.91
North-Western
Males 0.87 0.81 0.83 0.83 0.84 0.88 0.91 0.93 0.95 0.94 0.88
Females 0.85 0.81 0.87 0.88 0.88 0.90 0.92 0.94 0.95 0.94 0.90
South-Eastern
Males 0.96 0.94 0.94 0.95 0.96 0.97 0.98 0.98 0.98 0.99 0.96
Females 0.97 0.94 0.96 0.97 0.97 0.97 0.98 0.99 0.99 0.99 0.97
Southern
Males 0.97 0.95 0.96 0.96 0.97 0.98 0.98 0.99 0.99 0.99 0.97
Females 0.97 0.95 0.97 0.97 0.98 0.98 0.99 0.99 0.99 0.99 0.98
Western
Males 0.87 0.81 0.83 0.85 0.87 0.89 0.92 0.93 0.94 0.95 0.88
Females 0.87 0.81 0.89 0.88 0.89 0.91 0.93 0.94 0.95 0.95 0.90
Total 0.93 0.90 0.93 0.93 0.93 0.95 0.96 0.97 0.97 0.98 0.95
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those aged 0–11, and those aged 70+, being resident in
the midlands region and being female. These key findings
were replicated in 2021 and 2026. The main effects plot il-
lustrates age as the most significant driver of cost com-
pared to the other two variables, gender and region
(Figure 3). These results show a similar picture for
2021 and 2026 (Figure 4).
Discussion
Population growth, aging population and high fertility
rates will be drivers of future health costs in Ireland.
Population growth is the effect of changes in the size of
the population on total drug spending. Other things be-
ing equal, an increase in population size will increase
total drug spending. It is well documented in the litera-
ture that population is a driver of Irish health care ex-
penditure [22,23]. We estimate that the Irish population
will have increased by approximately 33 per cent by
2026. Population aging is the effect of changes in the age
distribution of the population on spending. An agingpopulation will result in increased spending as the use
and cost of drugs increase with age for the average in-
dividual within the population. Furthermore, Ireland
has the highest fertility rate (2.05) in the European
Union (EU27) as of March 2013. According to Eurostat,
Ireland has on average two live births per woman [24].
The CSO recorded 72,225 births in 2012, a 19.3 per cent
increase on 2002 births, indicating fertility will be a driver
of population growth going forward [25]. This is com-
pounded in our results with the 0–11 age cohort as a key
driver of future health care costs. A Canadian study found
population growth and population aging had the least ef-
fect on drug spending with volume effects and the mix of
drugs having the most significant effect of the six cost
drivers [7].
It is argued that a shift in the proportion of the popu-
lation being elderly causes a shift in the health care ex-
penditure in fifteen EU countries [26]. That is, as people
are living longer, it represents a shift in expenditure
from one age group to another. According to the latest
CSO life tables, male life expectancy has increased by
Table 2 Mean scenario average cost per claim (€) by gender, age & region 2007
Region 0 – 11 12 – 15 16 – 24 25 – 34 35 – 44 45 – 54 55 – 64 65 – 69 70 – 74 >75 Total
Eastern
Males 228.09 352.31 468.36 663.13 715.28 1024.07 1225.56 1301.78 1111.03 1261.80 835.14
Females 250.13 314.96 370.39 434.52 622.62 1036.64 1182.49 1339.82 1233.99 1565.85 835.14
Midlands
Males 252.32 346.52 570.72 862.57 843.18 1053.12 1212.19 1306.25 1374.38 1483.05 930.43
Females 286.53 287.65 433.68 527.21 784.65 1039.87 1280.93 1344.24 1510.02 1809.51 930.43
Mid-Western
Males 312.55 518.26 632.72 780.04 943.63 946.39 1122.24 1150.38 1145.96 1224.23 877.64
Females 331.60 391.68 381.46 574.27 779.34 1001.62 1261.18 1233.93 1298.71 1522.60 877.64
North-Eastern
Males 287.17 387.18 546.40 807.66 811.09 919.99 1136.46 1141.29 1192.14 1363.01 859.24
Females 290.24 438.25′ 324.13 502.04 671.81 970.68 1129.80 1329.20 1337.70 1598.56 859.24
North-Western
Males 224.88 313.54 411.39 607.13 721.31 792.40 909.40 976.33 958.41 1216.81 713.16
Females 257.50 264.09 294.35 388.02 566.78 767.27 1016.47 1076.26 1102.82 1398.05 716.16
South-Eastern
Males 272.48 397.70 591.81 817.17 846.95 1009.93 1087.12 1150.66 1200.19 1286.47 866.05
Females 247.29 389.64 380.57 454.17 753.83 1114.55 1223.04 1277.73 1314.70 1504.99 866.05
Southern
Males 310. 32 407.65 617.11 884.82 891.47 1039.17 1228.63 1315.09 1223.99 1265.83 918.41
Females 357.49 454.20 416.13 583.39 754.74 1132.37 1240.35 1375.76 1380.47 1489.19 918.41
Western
Males 298.90 375.46 555.50 865.61 822.04 935.52 1069.00 1199.25 1124.97 1307.75 855.40
Females 321.00 322.29 339.24 563.25 744.94 1035.37 1123.41 1238.10 1330.83 1535.57 855.40
Total 283.03 372.59 458.37 644.69 767.10 988.69 1153.02 1234.75 1240.02 1427.08 856.14
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Figure 2 Historical projections and projected pharmacy cost (€’000 m) to 2026.
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Table 3 Descriptive analysis of average cost per claimant (€) 2016 – 2026 (Scenario 2)
Year # of Simulations Mean SE Mean St. Dev Min Q1 Median Q3 Max
2016 100,000 272.31 0.912 149.32 69.63 106.19 167.59 286.14 1541.72
2021 100,000 312.61 0.994 314.45 78.65 121.29 190.43 330.86 1579.73
2026 100,000 366.81 1.18 272.28 86.68 135.56 241.10 371.60 1602.28
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http://www.biomedcentral.com/1472-6963/14/4775.8 years between 1996 and 2006 and 4.9 years for fe-
males [27]. This may justify the addition of a 12th HSE
age cohort, the >80s and renaming >75 s to 75–79 to
represent a shift in population where people are living
longer.
Population growth, aging population and high fertility
rates under existing policies will have a knock on effect
on future GMS coverage rates. That is, more people will
be eligible for medical cards. Since July 2001, everyone
over the age of 70 had a free entitlement to a medical
card. In 2005, General Practitioner Visit Cards (GPVC)
were introduced for persons who did not qualify for a
medical card. This card allows one to obtain free general
practitioner services subject to eligibility criteria. This
initiative was extended to all children under five years of
age in the Irish budget, 2014. In 2005, 5,079 people were
entitled to a GPVC [28] but by 2011 this increased to
125,657 [5].
In January 2009, eligibility for the GMS scheme chan-
ged for the over 70s. New medical card income limitsMF
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Figure 3 Statistical analysis Scenario 1 – Scenario 3, 2016.were introduced. A single person with an income of
€700 per week (€36,500 per year) or a couple with an in-
come of €1,400 per week (€73,000 per year) were no lon-
ger entitled to a free medical card [23]. Budget 2014
reduced the income limits to €500 per week for a single
person and €900 per week for a married couple [29].
This policy change will reduce the eligibility rates and
reduce overall coverage rates, holding all other factors
constant. Since the introduction of this policy change, it
is difficult to quantify the impact of this policy as the
Irish economy is still in recession with more people eli-
gible for the medical card due to their economic circum-
stances. Due to the three drivers of future health costs
as mentioned above, GMS coverage is likely to increase
thus increasing health costs. To counter this increase,
the Irish government may need to consider further de-
creasing the income limits for medical cards or other
measures.
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http://www.biomedcentral.com/1472-6963/14/477between 2003 and 2009 in terms of the average pharmacy
cost per eligible GMS person. The Midlands cost ranged
from €649.14 in 2003 to €943.28 in 2009 and the North-
West ranged from €521.91 and €787.19 over the same
time period [30]. Our results show that this trend is fore-
casted to continue to 2026. This regional variation in cost
may be explained by the following two studies. The distri-
bution of chronic conditions was examined across the old
health board regions and it was found the Midlands had
the highest prevalence of chronic conditions with the
Western and North-Western regions having the lowest
[15]. The prescribing prevalence of insulin dependent and
non-insulin dependent diabetes was examined across re-
gions [16]. They found the Midlands and the Mid-Western
regions had the highest prescribing ratios for both types of
diabetes and the North-Western region had the lowest pre-
scribing ratio. It is well documented that females visit doc-
tors more regularly than men, hence prescribing rates are
higher for females with a resulting effect of higher health
costs. Our results verify this, with females forecasting
higher costs than males for all scenarios.
The claims rate, i.e. the proportion who make a claim
on a medical card, has been above 90% since 2002. The
Irish government introduced a patient co-payment sys-
tem in October 2010 for medical card holders with a 50
cent per prescription charge, capped at €10 per month
and in Budget 2014, this was increased to €2.50 perprescription item, with a monthly cap of €25 [29]. The
prescription charge was introduced to reduce the claims
rate and the average cost per claim. Research found the 50
cent co-payment charge did not affect patient demand for
drugs [18]. No research has been done on subsequent in-
creases in the patient co-payment Irish system. More ex-
pensive co-payment charges exist in the UK [31], Italy
[32] and Australia [33]. These studies show that an expen-
sive co-payment system can affect the utilisation and de-
mand for drugs. It is well documented in the literature
that co-payment charges can reduce the utilisation of both
essential and non-essential medicines in vulnerable popu-
lations such as the poor, elderly and chronically ill [34,35].
Therefore the Irish government needs to be mindful of
the ill-effects of future increases in prescription charges as
these groups comprise the GMS population in Ireland.
Limitations of Data: It is important to note the limita-
tions of this research. The PCRS sample data lacked a
unique user identifier. There is a possibility of some data
appearing twice in the dataset as we can’t identify indi-
vidual claims, but the influence of such cases is small
given the size of the sample database (192,000). The old
health board regions (8) are no longer comparable to the
current HSE regional structure (4), which was changed
in 2010. Further research with more recent data and cost
projections using the current regional structure would
prove very useful.
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Over the next decade, Ireland’s population will experi-
ence rapid growth. This growth coupled with an aging
population will result in an increase in both the coverage
rate and the claims rate, thus the projected increase in
overall prescribing costs. However, these costs can be
contained by government policy initiatives. A downward
adjustment of the income eligibility limits can be used to
curtail the coverage rates and upward adjustments to
the co-payment patient prescription charges can be uti-
lised to reduce the claims rate, thus curbing the overall
average cost per claim. Age (youngest and oldest), fe-
males and the Midlands region were found to have the
most significant effect on future drug costs in Ireland.
These projections remain subject to substantial uncer-
tainty given the variable nature of future economic
trends and policy decisions.
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